“Kura announced positive updated preliminary results from its phase II study of tipifarnib in patients with HRAS mutant head and neck squamous cell carcinoma (HNSCC) were presented at the 2018 Multidisciplinary Head and Neck Cancers Symposium. Kura Oncology reiterated that it expects to initiate a registrational study of tipifarnib in HRAS mutant HNSCC sometime in 2018. These data combined with the 2017 ASH data, and a patent issued for tipifarnib earlier this year, are leading us to increase our estimated potential price for tipifarnib. This increases our estimated revenue in 2020-2022 by 66.7% per year, and is leading us to increase our price target to $30 per share (from $17.50).”,” Cann’s analyst wrote.
Several other brokerages have also recently issued reports on KURA. Wedbush began coverage on shares of Kura Oncology in a research note on Wednesday, December 20th. They set an outperform rating and a $19.00 target price on the stock. BidaskClub cut shares of Kura Oncology from a hold rating to a sell rating in a research report on Tuesday, January 9th. Oppenheimer set a $18.00 price objective on shares of Kura Oncology and gave the company a buy rating in a report on Monday, December 11th. Citigroup boosted their price target on shares of Kura Oncology from $15.00 to $19.00 and gave the stock a buy rating in a research note on Thursday, November 9th. Finally, ValuEngine lowered shares of Kura Oncology from a hold rating to a sell rating in a research note on Friday, December 1st. One research analyst has rated the stock with a sell rating, one has issued a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company’s stock. Kura Oncology currently has an average rating of Buy and an average target price of $21.67.
Kura Oncology (NASDAQ KURA) traded down $2.00 during mid-day trading on Friday, reaching $20.60. 432,017 shares of the company were exchanged, compared to its average volume of 342,727. Kura Oncology has a one year low of $5.90 and a one year high of $24.02. The company has a quick ratio of 13.48, a current ratio of 13.48 and a debt-to-equity ratio of 0.07. The firm has a market cap of $622.44 and a PE ratio of -13.29.
Kura Oncology (NASDAQ:KURA) last posted its earnings results on Monday, March 12th. The company reported ($0.37) earnings per share for the quarter, missing the consensus estimate of ($0.36) by ($0.01). sell-side analysts anticipate that Kura Oncology will post -1.58 earnings per share for the current year.
A number of large investors have recently added to or reduced their stakes in the business. BlackRock Inc. increased its position in shares of Kura Oncology by 49.1% in the fourth quarter. BlackRock Inc. now owns 1,524,817 shares of the company’s stock valued at $23,331,000 after buying an additional 502,296 shares in the last quarter. Candriam Luxembourg S.C.A. acquired a new stake in shares of Kura Oncology during the third quarter valued at $8,073,000. Nexthera Capital LP boosted its stake in shares of Kura Oncology by 72.3% during the fourth quarter. Nexthera Capital LP now owns 445,550 shares of the company’s stock valued at $6,817,000 after acquiring an additional 187,034 shares during the last quarter. Vanguard Group Inc. boosted its stake in Kura Oncology by 13.0% in the 2nd quarter. Vanguard Group Inc. now owns 433,868 shares of the company’s stock worth $4,035,000 after buying an additional 50,033 shares during the last quarter. Finally, Millennium Management LLC boosted its stake in Kura Oncology by 35.7% in the 4th quarter. Millennium Management LLC now owns 303,905 shares of the company’s stock worth $4,650,000 after buying an additional 79,989 shares during the last quarter. Hedge funds and other institutional investors own 64.65% of the company’s stock.
COPYRIGHT VIOLATION WARNING: “Kura Oncology’s (NASDAQ:KURA) Buy Rating Reaffirmed at Cann” was reported by Equities Focus and is the property of of Equities Focus. If you are accessing this news story on another publication, it was illegally copied and reposted in violation of international trademark & copyright laws. The original version of this news story can be read at https://www.equitiesfocus.com/2018/03/14/kura-oncology-kura-rating-reiterated-by-cann.html.
Kura Oncology Company Profile
Kura Oncology, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in discovering and developing personalized therapeutics for the treatment of solid tumors and blood cancers. Its segment is engaged in the discovery and development of personalized therapeutics for the treatment of solid tumors and blood cancers.
Receive News & Ratings for Kura Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kura Oncology and related companies with MarketBeat.com's FREE daily email newsletter.